![]() Wasserberg N, Morgenstern S, Schachter J, Fenig E, Lelcuk S, Gutman H. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Sentinel node biopsy in ductal carcinoma in situ patients. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. ![]() ![]() Roses DF, Brooks AD, Harris MN, Shapiro RL, Mitnick J. Assessment of morbidity from complete axillary dissection. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Axillary lymphadenectomy for intraductal carcinoma of the breast. Silverstein MJ, Gierson ED, Colburn WJ, Rosser RJ, Waisman JR, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. McCready DR, Yong WS, Ng AKT, Miller N, Done S, Youngson B. Sentinel lymph node biopsy in patients with ductal carcinoma in situ: a proposal. McMasters KM, Chao C, Wong SL, Martin RCG, Edwards MJ. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Sentinel lymph node mapping and biopsy for ductal carcinoma in situ and other controversial indications. An argument against routine sentinel node mapping for DCIS. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2002 7:636–42įarkas EA, Stolier AJ, Teng SC, Bolton JS, Fuhrman GM. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Mapping a pathway for axillary staging: a personal perspective on the current status of sentinel lymph node dissection for breast cancer. Reanalysis and results after 12 years of follow-up in a radomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001 67:513–21įisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. J Am Coll Surg 2005 200:516–26Ĭox CE, Nguyen K, Gray RJ, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Kelly TA, Kim JA, Patrick R, Grundfest S, Crowe JP. Predicting nodal positivity in 2282 patients with breast carcinoma. Detection of ductal carcinoma in situ in women undergoing screening mammography. On the basis of our results, routine SLNB is recommended in this patient population.Įrsnter VL, Ballard-Barbash R, Barlow WE, et al. ConclusionsĪpproximately one-third of patients with DCIS treated with mastectomy at our institution later had invasive disease, and factors associated with invasion have been identified. There was no statistically significant predictor for sentinel lymph node metastasis. On multivariate analysis, comedonecrosis ( P = .04) and diagnosis by core biopsy ( P < .01) were independent predictors for invasion. On univariate analysis, multifocality ( P = .03), multicentricity ( P = .01), comedonecrosis ( P = .01), and diagnosis by core biopsy ( P < .001) were associated with invasive disease on pathology. Seven SLNB patients (13%) had positive SLNs. Overall, 30 patients (33%) had invasive disease, 22 of whom received concurrent SLNB. Of 44 patients diagnosed preoperatively with DCIS by core biopsy only, 34 patients (63%) had a concurrent SLNB, while 10 patients (28%) were treated with mastectomy alone ( P < .01). Ninety mastectomies for DCIS were included, 54 (60%) of which were performed with concurrent SLNB. MethodsĪ retrospective study was conducted of all mastectomies performed on patients with a preoperative diagnosis of DCIS between 20 at a single tertiary-care institution. The purpose of this study was to determine factors associated with the subsequent diagnosis of invasive disease and to determine the role of SLNB when performing a mastectomy for DCIS. Its role in ductal carcinoma-in-situ (DCIS) is unclear. Sentinel lymph node biopsy (SLNB) is a widely accepted alternative to axillary lymph node dissection in invasive breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |